Penumbra, Inc. (PEN) |
| 318.94 0.84 (0.26%) 07-13 16:00 |
| Open: | 317.63 |
| High: | 318.94 |
| Low: | 317.63 |
| Volume: | 344,016 |
| Market Cap: | 12,544(M) |
| PE Ratio: | 83.27 |
| Exchange: | New York Stock Exchange |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 376.86 |
| Resistance 1: | 322.65 |
| Pivot price: | 317.28 |
| Support 1: | 317.80 |
| Support 2: | 314.80 |
| 52w High: | 362.41 |
| 52w Low: | 221.26 |
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
| EPS | 4.330 |
| Book Value | 37.480 |
| PEG Ratio | 4.06 |
| Gross Profit | 24.916 |
| Profit Margin (%) | 11.76 |
| Operating Margin (%) | 10.20 |
| Return on Assets (ttm) | 6.7 |
| Return on Equity (ttm) | 12.7 |
Sat, 11 Jul 2026
Enterprise value to EBITDA forward of Penumbra, Inc. – NYSE:PEN - TradingView
Tue, 07 Jul 2026
First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke - PR Newswire
Tue, 07 Jul 2026
How Penumbra’s FORWARD Stroke Trial Could Shape THUNDERBOLT Catheter Adoption for PEN Investors - Sahm
Wed, 17 Jun 2026
Penumbra (PEN) Proxy filing Summary - Quartr
Fri, 05 Jun 2026
Here’s What Supports Penumbra’s (PEN) Revenue Growth and Margin Expansion - Yahoo Finance
Thu, 07 May 2026
Penumbra (NYSE: PEN) investors back merger, await antitrust approvals - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |